Profiling and determination of phenolic compounds in Indian marketed hepatoprotective polyherbal formulations and their comparative evaluation

Background: Nowadays, plants have been considered as powerful agents for treatment of disorders due to their traditional use. Plants have a special role in the treatment of various diseases in Ayurveda. Liver disorders with their devastating outcomes have been discussed in Ayurveda as well. Objectives: In the present study, polyherbal products (L52 and L38) were retrieved from Ayurveda and its pharmacognostic standardization was performed. Materials and methods: Quality control test for the Ayurveda tablets were performed as per Indian Pharmacopoeia. Dissolution studies of polyherbal Ayurveda marketed formulations were assessed based on the phenolic content. Fingerprinting of phytochemical constituents of L52 and L38 was performed using spectroscopical (like IR and UV) and chromatographic techniques like HPLC, HPTLC and TLC. Results: The results showed that L52 and L38 successfully passed quality control tests. Moreover, L52 and L38 exhibited different pharmacognostic behavior of all herbs present in the product. In addition, TLC, IR, HPTLC and HPLC fingerprinting of L52 and L38 demonstrated the presence of several phenolic constituents corresponding to the polyherbs. Conclusion: Regarding the role of phenolic compounds in the treatment of hepatitis, L52 and L38 could be appropriate candidates for hepatitis with respect to their traditional use in Ayurveda formulation. Moreover, HPTLC and HPLC fingerprinting could be utilized as an applicable method for quality control of the prepared formulation. Keywords: Fingerprinting, Ayurveda formulations, Dissolution studies, Standardization, Spectroscopical and chromatographic evaluatio

TARGETING ANGIOGENESIS WITH FLUPHENAZINE-ZINC OXIDE NANOCONJUGATES: A POTENTIAL MECHANISM FOR IMPROVING ANTIPSYCHOTIC EFFICACY

This study aimed to develop a more effective formulation of Fluphenazine (FLP) for the management of psychosis. Antipsychotics are widely used for the treatment of severe mental disorders such as schizophrenia and bipolar disorder. However, their clinical use is limited due to various side effects and low efficacy in a large number of patients. Nanoparticle-based drug delivery systems have shown great potential in improving the pharmacokinetics and pharmacodynamics of various drugs, including antipsychotics. Zinc oxide nanoparticles (ZnO NPs) have emerged as a promising carrier for drug delivery due to their unique physicochemical properties, biocompatibility, and low toxicity. In this study, we reported the preparation and characterization of FLU encapsulated ZnO NPs (FLU-ZnO-NPs) for the management of psychosis. The synthesized FLU-ZnO-NPs were characterized using various techniques, such as X-Ray Diffractometer, Energy Dispersive X-Ray analysis, Transmission Electron Microscopy, and Zetasizer (Malvern). The characterization results showed that the synthesized FLU-ZnO-NPs had improved solubility, enhanced bioavailability, targeted delivery, and reduced toxicity. The development of FLU-ZnO-NPs could provide a more effective and safe treatment option for patients with mental disorders